Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study WJ Sandborn, SD Lee, D Tarabar, E Louis, M Klopocka, J Klaus, ... Gut 67 (10), 1824-1835, 2018 | 111 | 2018 |
Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems R Tasseff, S Nayak, S Salim, P Kaushik, N Rizvi, JD Varner PLoS One 5 (1), e8864, 2010 | 42 | 2010 |
A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials S Nayak, S Salim, D Luan, M Zai, JD Varner PLoS One 3 (4), e2016, 2008 | 32 | 2008 |
Modelling and analysis of an ensemble of eukaryotic translation initiation models S Nayak, JK Siddiqui, JD Varner IET systems biology 5 (1), 2-14, 2011 | 30 | 2011 |
Modeling and analysis of retinoic acid induced differentiation of uncommitted precursor cells R Tasseff, S Nayak, SO Song, A Yen, JD Varner Integrative biology 3 (5), 578-591, 2011 | 29 | 2011 |
Anti-MAdCAM antibody increases ß7+ T cells and CCR9 gene expression in the peripheral blood of patients with Crohn’s disease M Hassan-Zahraee, A Banerjee, JB Cheng, W Zhang, A Ahmad, K Page, ... Journal of Crohn's and Colitis 12 (1), 77-86, 2018 | 28 | 2018 |
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML–RARα negative human myeloblastic … S Nayak, M Shen, RP Bunaciu, SE Bloom, JD Varner, A Yen Leukemia & lymphoma 51 (9), 1-14, 2010 | 27 | 2010 |
Computational modeling and analysis of insulin induced eukaryotic translation initiation J Lequieu, A Chakrabarti, S Nayak, JD Varner PLoS computational biology 7 (11), e1002263, 2011 | 25 | 2011 |
Using a systems pharmacology model of the blood coagulation network to predict the effects of various therapies on biomarkers S Nayak, D Lee, S Patel‐Hett, DD Pittman, SW Martin, AC Heatherington, ... CPT: pharmacometrics & systems pharmacology 4 (7), 396-405, 2015 | 24 | 2015 |
Getting innovative therapies faster to patients at the right dose: impact of quantitative pharmacology towards first registration and expanding therapeutic use S Nayak, O Sander, N Al‐Huniti, D de Alwis, A Chain, M Chenel, ... Clinical Pharmacology & Therapeutics 103 (3), 378-383, 2018 | 23 | 2018 |
A dynamic quantitative systems pharmacology model of inflammatory bowel disease: Part 1–model framework KV Rogers, SW Martin, I Bhattacharya, RSP Singh, S Nayak Clinical and Translational Science 14 (1), 239-248, 2021 | 16 | 2021 |
Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach S Koride, S Nayak, C Banfield, MC Peterson CPT: Pharmacometrics & Systems Pharmacology 8 (7), 478-488, 2019 | 16 | 2019 |
Long-term safety and efficacy of the anti-mucosal addressin cell adhesion molecule-1 monoclonal antibody ontamalimab (SHP647) for the treatment of Crohn’s disease: the OPERA II … GR D’Haens, W Reinisch, SD Lee, D Tarabar, E Louis, M Kłopocka, ... Inflammatory Bowel Diseases 28 (7), 1034-1044, 2022 | 11 | 2022 |
Transforming translation through quantitative pharmacology for high‐impact decision making in drug discovery and development N Gupta, D Bottino, USH Simonsson, CJ Musante, T Bueters, TR Rieger, ... Clinical Pharmacology & Therapeutics 107 (6), 1285-1289, 2020 | 10 | 2020 |
A dynamic quantitative systems pharmacology model of inflammatory bowel disease: Part 2–application to current therapies in Crohn’s disease KV Rogers, SW Martin, I Bhattacharya, RSP Singh, S Nayak Clinical and Translational Science 14 (1), 249-259, 2021 | 8 | 2021 |
Know your variability: challenges in mechanistic modeling of inflammatory response in inflammatory bowel disease (IBD) KV Rogers, I Bhattacharya, SW Martin, S Nayak Clinical and Translational Science 11 (1), 4, 2018 | 7 | 2018 |
A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non‐bleeding subjects D Lee, S Nayak, SW Martin, AC Heatherington, P Vicini, F Hua Journal of Thrombosis and Haemostasis 14 (12), 2430-2445, 2016 | 7 | 2016 |
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective R Zhu, B Vora, S Menon, I Younis, G Dwivedi, Z Meng, A Datta‐Mannan, ... Clinical Pharmacology & Therapeutics 114 (4), 751-767, 2023 | 6 | 2023 |
Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage R Schoemaker, S Nayak, LO Harnisch, MO Karlsson, ... Journal of Pharmacokinetics and Pharmacodynamics 46 (5), 473-484, 2019 | 3 | 2019 |
A review of quantitative modeling of B cell responses to antigenic challenge TP Hickling, X Chen, P Vicini, S Nayak Journal of Pharmacokinetics and Pharmacodynamics 41 (5), 445 - 459, 2014 | 3 | 2014 |